Your browser doesn't support javascript.
loading
Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.
Meynard, Lucie; Dinart, Derek; Delaunay, Blandine; Fléchon, Aude; Saldana, Carolina; Lefort, Félix; Gravis, Gwenaëlle; Thiery-Vuillemin, Antoine; Cancel, Mathilde; Coquan, Elodie; Ladoire, Sylvain; Maillet, Denis; Rolland, Frédéric; Boughalem, Elouen; Martin, Sophie; Laramas, Mathieu; Crouzet, Laurence; Abbar, Baptiste; Falkowski, Sabrina; Pouessel, Damien; Roubaud, Guilhem.
Affiliation
  • Meynard L; Department of Medical Oncology, Institut Bergonié, Bordeaux, France. Electronic address: lucie.meynard@gmail.com.
  • Dinart D; University Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, F-33000 Bordeaux, France; Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France.
  • Delaunay B; Department of Medical Oncology, Institut Claudius Régaud, IUCT Oncopole, Toulouse, France.
  • Fléchon A; Department of Medical Oncology, Centre Léon Bérard, Lyon, France.
  • Saldana C; AP-HP, Hopital Henri Mondor, Service d'Oncologie, Univ Paris Est Creteil, TRePCa, F-94010 Creteil, France.
  • Lefort F; Department of Medical Oncology, University Hospital, Bordeaux, France.
  • Gravis G; Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France.
  • Thiery-Vuillemin A; Department of Medical Oncology, University Hospital Jean Minjoz, Besançon, France.
  • Cancel M; Department of Medical Oncology, University Hospital, Tours, France.
  • Coquan E; Department of Medical Oncology, Centre François Baclesse, Caen, France.
  • Ladoire S; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Maillet D; Department of Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Lyon, France.
  • Rolland F; Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.
  • Boughalem E; Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Angers, France.
  • Martin S; Department of Medical Oncology Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
  • Laramas M; Department of Medical Oncology, University Hospital, Grenoble, France.
  • Crouzet L; Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.
  • Abbar B; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Medical Oncology, Institute Universitaire de Cancérologie, CLIP(2) Galilée, Paris, France.
  • Falkowski S; Department of Medical Oncology, Clinique François Chénieux, Limoges, France.
  • Pouessel D; Department of Medical Oncology, Institut Claudius Régaud, IUCT Oncopole, Toulouse, France.
  • Roubaud G; Department of Medical Oncology, Institut Bergonié, Bordeaux, France.
Eur J Cancer ; 175: 43-53, 2022 11.
Article in En | MEDLINE | ID: mdl-36088671
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell Type of study: Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Eur J Cancer Year: 2022 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell Type of study: Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Eur J Cancer Year: 2022 Type: Article